KETAMINE FOR ANALGESIA

SUMMARY
Ketamine is a dissociative/hypnotic agent historically used for anesthesia. In the 1980s, its analgesic properties were discovered, and significant data now exists on its use in pain management in the perioperative setting. Ketamine has been shown to be a safe and effective treatment for perioperative pain, although optimal dosing strategies and efficacy for individual surgical subpopulations have yet to be established.

RECOMMENDATIONS

- **Level 1**
  - None

- **Level 2**
  - Ketamine, at sub-dissociative doses (<0.5 mg/kg/hour IV), may be considered in patients with moderate to severe pain as part of a multimodal pain control strategy to decrease opioid requirements.
  - Consider sub-dissociative ketamine in patients with significant burn injuries where adequate analgesia is not obtained with opioid-based regimens.
  - Ketamine should be avoided in patients with the following conditions:
    - History/current myocardial ischemia, arrhythmias, or significant increase in blood pressure/heart rate
    - Severe pulmonary secretions
    - History of / current glaucoma
    - Psychiatric history

- **Level 3**
  - Sub-dissociative ketamine dosing strategies include:
    - Intermittent IV bolus: Ketamine IV 0.3 mg/kg over 15 minutes
    - Continuous IV infusion: Ketamine IV 0.1 – 0.3 mg/kg/hour x 24-72 hours
    - Enteral: Ketamine PO 4 – 6 mg/kg
      - Give 30 minutes prior to burn dressing change
      - Give concomitant benzodiazepine to reduce psychomimetic effects

INTRODUCTION
Ketamine is a dissociative/hypnotic agent initially developed as a derivative of phencyclidine (PCP) for general anesthesia. After widespread use during the Vietnam War, ketamine was approved by the FDA in 1970 as an amnestic agent. Ketamine mainly acts through antagonism of N-methyl-D-aspartate (NMDA)

EVIDENCE DEFINITIONS

- **Class I**: Prospective randomized controlled trial.
- **Class II**: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies.
- **Class III**: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion.
- **Technology assessment**: A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness.

LEVEL OF RECOMMENDATION DEFINITIONS

- **Level 1**: Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation.
- **Level 2**: Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence.
- **Level 3**: Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research.
receptors causing functional and electrophysiological dissociation. The use of ketamine as an analgesic agent began in the 1980s when the NMDA receptor was discovered to have a major role in the processing of pain, particularly in the central nervous system. Through NMDA receptor antagonism, ketamine attenuates centrally-mediated pain processes to reduce the development of opioid tolerance and opioid-induced hyperalgesia (1). In addition to action on NMDA receptors, ketamine also acts as a weak opioid receptor agonist, alpha-1 and beta-2 receptor agonist, and muscarinic acetylcholine receptor inhibitor (2,3). The analgesic properties of ketamine are observed at sub-anesthetic doses (<1 mg/kg IV bolus dose and <0.5 mg/kg/hr IV continuous infusion).

Ketamine has a rapid onset of action of 1-1.5 minutes and duration of action of 30-60 minutes (2,3). Ketamine is highly lipid soluble and crosses the blood brain barrier to exert its central nervous system (CNS) effects. Ketamine undergoes extensive first pass metabolism and has poor absorption orally; therefore, intravenous dosing is the optimal mode of administration. However, there is evidence for using orally administered ketamine as adjunct analgesia for burn dressing changes, as the major metabolite (norketamine) is thought to exert similar effects as the parent compound (15).

When utilized for analgesia, ketamine is administered at doses lower than when used as an anesthetic agent. Compared to anesthetic doses, sub-dissociative dosing of ketamine (<1 mg/kg IV bolus dose and <0.5 mg/kg/hr IV continuous infusion) is advantageous due to the lower risk of side effects. Adverse effects include neurologic (psychotomimetic effects), cardiovascular (hypertension and tachyarrhythmias), and respiratory (hypersalivation and laryngospasm). Although rare, cystitis has also been reported. The most notable of these are the psychotomimetic effects which include delirium, delusions, bad dreams, and hallucinations. These side effects can be mitigated with concomitant use of benzodiazepines, with midazolam being the most commonly utilized agent. Psychotomimetic effects are dose-dependent; therefore, the risk of development is higher with increased doses. Psychotomimetic effects occur in 7-8% of patients given sub-dissociative doses compared to 3.6-5% in placebo patients (1). Cardiac adverse effects including hypertension and tachyarrhythmias result from ketamine’s action on alpha and beta-receptors. These effects are often transient, do not require treatment, and are most often associated with anesthetic doses (1). Ketamine can also cause increases in secretions leading to hypersalivation, although this has not been reported at sub-anesthetic doses. Hypersalivation can be treated with an antisecretory agent such as glycopyrrolate or scopolamine.

Ketamine is a potent analgesic at sub-dissociative doses ranging from 0.1-0.5 mg/kg when used for bolus dosing (8,9). Administration of continuous infusion ketamine for analgesia ranges from 0.06-0.6 mg/kg/hr (1-10). Of note, doses <0.1 mg/kg/hr are less likely to be effective. Several studies have assessed the use of low-dose ketamine infusion for post-operative pain control and demonstrated a 20-30% reduction in morphine use (4-10). Although utilization of ketamine as a component of multimodal pain control has demonstrated reduction in opioid usage, studies have not consistently shown a reduction in pain scores when compared to standard pain management consisting of mainly opioids. The lack of positive results with pain scores as an outcome could be misleading due to the fact that patients in the control groups were receiving pain medications to treat elevated pain scores; therefore, reduction of opioid use is most likely the more important outcome. Additionally, the long-term effects of administration of continuous infusion ketamine greater than 72 hours have not been assessed (1).

An advantage of ketamine over opioid agents for analgesia is that it does not cause respiratory depression making it an attractive agent for patients who are not mechanically ventilated. In addition, ketamine maintains hemodynamic stability through action on alpha and beta receptors suggesting an advantage in patients with concern for hemodynamic instability, such as patients with severe burn injuries during the acute resuscitation phase. These attributes make ketamine an attractive option for patients who have undergone procedures associated with significant chronic pain (i.e., abdominal, thoracotomies, etc.) or injuries associated with significant pain (i.e., rib fractures, orthopedic injuries, burn injuries). However, few studies have assessed the utilization of ketamine for specific surgical procedures or injury types.

Tolerance to the analgesic and sedative agents leads to increased doses in order to maintain adequate sedation and analgesia during the procedure. For patients with significant burns (>20% total body surface
area), two problems emerge: 1) prolonged recovery after each dressing change due to high opioid and benzodiazepine doses and 2) heterotopic ossification as a result of pain-limited mobility. The addition of ketamine to a regimen of opioids and benzodiazepines for dressing changes may not only decrease the opioid and benzodiazepine requirements, but also facilitate improved compliance with physical and occupational therapy leading to a decreased incidence of heterotopic ossification (16). Patients with severe burn injuries are often hemodynamically unstable early in their course and could benefit from ketamine’s effects on alpha and beta receptors as well.

With minimal risk of causing significant adverse effects, low-dose ketamine does not require extensive monitoring. Therefore, with appropriate education of nursing staff, bolus dosing and continuous infusion of low-dose ketamine can be administered on all levels of care. This is supported in the literature with institutions describing the safe and effective use of low-dose ketamine in patients admitted to general medical/surgical floors (11,12).

**LITERATURE REVIEW**

**Postoperative Pain Management**

Guillou et al. compared the use of ketamine to placebo in a randomized, double-blinded study of surgical intensive care unit patients who had undergone major abdominal surgery. The primary outcome of the study was morphine consumption. All patients received a morphine patient-controlled analgesia (PCA) pump for 48 hours. Ninety-three patients were included in the study. The mean age was 60 years in both groups and the most common surgeries performed were hepatectomy followed by esophageal surgery. Mean Simplified Acute Physiology Scores (SAPS) were 30 for both groups indicating a relatively low mortality rate. Patients in the ketamine group received an initial bolus of 0.5 mg/kg followed by an infusion of 0.12 mg/kg/hr for the first 24 hours followed by 0.06 mg/kg/hr for another 24 hours. The study found that although visual analog pain scale scores were not significantly different, there was a significant difference in morphine consumption between the ketamine group (53 mg) compared to the morphine-only group (80 mg). There was no significant difference in adverse effects between the two groups (4).

Adriaenssens et al. conducted a double-blind, randomized study of thirty laparotomy patients administered a ketamine infusion of 0.15 mg/kg/hr for 48 hours along with a morphine PCA pump for post-operative pain compared to placebo. There was no difference in visual analogue pain scores. The study found a significant reduction in morphine consumption at 48 hours; 28 mg in the ketamine group compared to 54 mg in the morphine group (p=0.0003). There was no significant difference in adverse effects except for less nausea in the ketamine group (p=0.03) (5).

Remerand et al. compared the use of continuous low-dose ketamine to placebo for 154 patients who underwent total hip arthroplasty with the primary outcome of 24-hour morphine use. The ketamine group received an intraoperative ketamine bolus of 0.5 mg/kg followed by a continuous infusion of 0.12 mg/kg/hr for 24 hours. In addition to ketamine and morphine, all patients received a single dose of paracetamol and scheduled ketoprofen postoperatively. The study found a 28% reduction in morphine consumption within the first 24 hours of ketamine infusion. There was no significant difference in pain score between the two groups and a non-significant reduction in the incidence of nausea in the ketamine group (6).

Yamauchi et al. assessed two different ketamine infusion strategies versus placebo in 200 post-cervical or post-lumbar surgery patients. The primary outcome of the study was postoperative fentanyl consumption. Patients in the ketamine group received either a bolus of 1 mg/kg followed by a continuous infusion of 0.042 mg/kg/hr or a bolus of 1 mg/kg followed by a continuous infusion of 0.083 mg/kg/hr for 24 hours. All patients received a fentanyl PCA programmed to administer a basal infusion along with an on-demand dose every 6 minutes. For both post-cervical and post-lumbar surgery patients, there was a significant decrease in pain score in patients who received infusions of 0.083 mg/kg/hr compared to the 0.042 mg/kg/hr or placebo groups. Additionally, post-cervical surgery patients received lower overall fentanyl and NSAID consumption. Post-lumbar surgery patients received less fentanyl compared to placebo up until 6 hours of the infusion. The only significant adverse effects noted were nausea and vomiting which were lower in the higher ketamine infusion group (7).
Laskowski et al. conducted a meta-analysis of 47 double-blind randomized studies of intravenous ketamine used for perioperative or postoperative pain control. Patients who underwent abdominal or thoracic procedures showed the greatest reduction in opioid use. Patients who underwent orthopedic, intra-abdominal and pelvic surgeries also showed decreased opioid use. Although no serious adverse effects were noted, patients who received ketamine experienced increased neuropsychiatric effects (7.4% versus 3%) and decreased post-operative nausea and vomiting (25.6% versus 30.4%). The majority of studies utilized doses less than 0.5 mg/kg. The meta-analysis did not report the mean duration of ketamine administration (8).

Jouguelet-Lacoste et al. conducted a systematic review of 39 clinical trials and five meta-analyses assessing perioperative low-dose intravenous continuous infusion or intravenous bolus of ketamine. All the meta-analyses found a reduction in pain scores and opioid consumption postoperatively. In studies assessing postoperative infusions of ketamine, the majority of studies utilized infusions between 0.042-0.18 mg/kg/hr. There was limited reduction in opioid consumption in trials which utilized ketamine infusions <0.10 mg/kg/hr. Only one study of postoperative ketamine infusion utilized pain score reduction as the primary outcome and concluded administration of ketamine reduced postoperative pain. The studies utilized ketamine postoperatively for 24-48 hours with or without IV boluses prior to initiation of the infusions. The analysis concluded that low dose administration of ketamine was safe and effective for management of postoperative pain (9).

Analgesia in Trauma Patients
Polomano et al. conducted a retrospective review of 19 patients with combat wounds with major limb trauma treated with low-dose continuous infusion ketamine for 3 days. Patients had failed conventional pain treatments including multimodal analgesia and regional anesthesia techniques. The majority of patients sustained traumatic or surgical amputations of one limb. Ketamine infusions were initiated at 0.12 mg/kg/hr with dose adjustments in only three patients. Overall, there was no significant reduction in opioid requirements. However, patients experienced a significant decrease in reported pain while on ketamine compared to opioid therapy alone (13).

Losing et al. described a case series of three multi-trauma patients treated with low dose continuous infusion ketamine for pain control. Patient ages ranged from 26-65 years old and all patients suffered from rib fractures. Ketamine dosing ranged from 0.06-6 mg/kg/hr. Opioid requirements decreased in all patients after initiation of ketamine. A dissociative adverse effect occurred in one patient requiring reduction of the ketamine infusion and subsequent discontinuation (14).

Analgesia in Burn Dressing Changes
MacPherson et al. conducted a prospective study on the use of a combination ketamine/midazolam PCA for burn dressing changes. Each PCA contained ketamine 200mg and midazolam 10mg in 20 mL of normal saline. The PCA was programmed to provide demand doses of ketamine 20mg and midazolam 0.5mg every three minutes; there was no basal rate. 44 patients were evaluated during 95 procedures used a mean of 9 mL per procedure (~ketamine 180mg/midazolam 4.5mg). At the end of the procedure, patients and staff rated the effectiveness of the treatment on a scale of 1 to 10 (best) – with an average score of 8.5/10 for both patients and staff (calculated median = 9/10). Adverse events were noted in 15/44 patients with the most frequent being hallucinations (11/44) and desaturations < 95% (5/44). The authors concluded that this PCA provided adequate and effective analgesia (17).

Newton et al. conducted a prospective, observational study on the use of intravenous ketamine for procedural sedation in adult patients (age > 16 years) (18). Patients were excluded if they had an abnormal airway, current respiratory infection, traumatic brain injury, ocular injury, increased intraocular pressure, cardiac disease, psychotic illness, uncontrolled hypertension, hyper- or hypothyroidism, porphyria, or an allergy to ketamine. Patients received an initial dose of ketamine 0.5mg/kg IV which was repeated in 5 minutes if adequate sedation was not achieved. They enrolled 92 patients and achieved adequate sedation in 91 of the 92 patients (98.9%). Twenty of the 92 patients experienced adverse events, 12 of which were emergence-related reactions.
Gündüz et al. conducted a prospective, randomized trial comparing the use of ketamine alone compared with ketamine + dexmedetomidine or ketamine + midazolam during dressing changes in burn patients for dressing changes in the operating room – non-intubated patients (19). Patients received placebo, dexmedetomidine (1 mcg/kg) or midazolam (0.05 mg/kg) 10 minutes before ketamine 1 mg/kg IV bolus. An additional ketamine dose of 1 mg/kg would be administered for visual-analog scale pain scores ≥ 5. There were no significant differences between the groups with respect to pain scores during & after the dressing change, duration of dressing change or recovery time after the dressing change. There was significantly more sedation in the ketamine + dexmedetomidine group. There was one episode of hallucinations occurred in the ketamine + dexmedetomidine group and one patient in the ketamine only group developed hallucinations.

Ezike et al. evaluated escalating doses of ketamine administered orally for analgesia during burn dressing changes in adult burn patients to determine the dosing range with the best benefit/risk profile. They randomly assigned 240 wound care procedures to 6 treatment groups: (A) 0.5 mg/kg, (B) 2 mg/kg, (C) 4 mg/kg, (D) 6 mg/kg, (E) 8 mg/kg, and (F) 10 mg/kg. Groups A and B reported higher levels of pain, while groups C, D, E, and F reported varying levels of efficacy. E and F had the best analgesic profiles, however they also had the highest incidence of adverse effects in addition to some patients becoming anesthetized. The authors concluded that 4-6 mg/kg was the dosing range with the best efficacy/safety profile. Of note, in these 2 groups hallucinations occurred in 10-15% of patients, and hypersalivation occurred in 17.5-20%. Additionally, mean arterial blood pressure increased 17.6-22.1% from baseline, with an accompanying 31.6-32.9% increase in heart rate (15).

REFERENCES

Surgical Critical Care Evidence-Based Medicine Guidelines Committee

Revision Author: Dominick Curry, Pharm.D., BCCCP
Previous Authors: Hilary Silvestri, PharmD; Brandon Hobbs, PharmD
Editor: Michael L. Cheatham, MD; Chadwick Smith, MD
Last revision date: December 26, 2019

Please direct any questions or concerns to: webmaster@surgicalcriticalcare.net